NASDAQ:IVVD

Invivyd (IVVD) Stock Forecast, Price & News

$1.30

-0.05 (-3.70%)

(As of 06/9/2023 ET)

Compare

Today's Range: $1.27
▼
$1.35
50-Day Range: $1.08
▼
$1.80
52-Week Range: $1.03
▼
$4.90

Volume: 200,309 shs
Average Volume: 226,420 shs
Market Capitalization: $142.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Invivyd MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 130.8% Upside
$3.00 Price Target
Short Interest: Bearish
8.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.35) to ($0.98) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

915th out of 987 stocks

Biological Products, Except Diagnostic Industry

153rd out of 159 stocks

3.0

Analyst's Opinion

Consensus Rating
Invivyd has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Invivyd has a forecasted upside of 130.8% from its current price of $1.30.
Amount of Analyst Coverage
Invivyd has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
8.19% of the float of Invivyd has been sold short.
Short Interest Ratio / Days to Cover
Invivyd has a short interest ratio ("days to cover") of 14, which indicates bearish sentiment.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Invivyd does not currently pay a dividend.
Dividend Growth
Invivyd does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVVD.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Invivyd this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Invivyd insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.89% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Invivyd are expected to grow in the coming year, from ($1.35) to ($0.98) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Invivyd is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Invivyd is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Invivyd has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

IVVD Stock News Headlines

May 23, 2023 | finance.yahoo.com

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

May 19, 2023 | americanbankingnews.com

Q2 2023 Earnings Estimate for Invivyd, Inc. (NASDAQ:IVVD) Issued By HC Wainwright

June 9, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 18, 2023 | americanbankingnews.com

Q4 2024 EPS Estimates for Invivyd, Inc. Decreased by HC Wainwright (NASDAQ:IVVD)

May 13, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Invivyd, Inc.'s Q1 2024 Earnings (NASDAQ:IVVD)

May 12, 2023 | marketwatch.com

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023 | msn.com

Invivyd: Q1 Earnings Insights

May 11, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Invivyd (IVVD)

June 9, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 10, 2023 | msn.com

4IVVD : Earnings Preview: Invivyd

May 4, 2023 | finance.yahoo.com

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

May 1, 2023 | americanbankingnews.com

HC Wainwright Initiates Coverage on Invivyd (NASDAQ:IVVD)

April 25, 2023 | benzinga.com

Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

April 25, 2023 | finance.yahoo.com

Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference

April 25, 2023 | finance.yahoo.com

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

April 14, 2023 | finance.yahoo.com

After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)

March 31, 2023 | benzinga.com

INVIVYD DEADLINE ALERT: Bragar Eagel & Squire...

March 30, 2023 | finance.yahoo.com

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

March 30, 2023 | americanbankingnews.com

Invivyd (NASDAQ:IVVD) Price Target Lowered to $1.00 at Morgan Stanley

March 29, 2023 | prnewswire.com

IVVD FINAL DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI

March 29, 2023 | benzinga.com

IVVD LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of INVIVYD, INC. F/K/A ADAGIO THERAPEUTICS, INC. Shareholders

March 29, 2023 | benzinga.com

IVVD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Invivyd, Inc. f/k/a Adagio Therapeutics, Inc.

March 28, 2023 | finance.yahoo.com

Invivyd, Inc. (NASDAQ:IVVD) Q4 2022 Earnings Call Transcript

March 24, 2023 | benzinga.com

Invivyd, Inc. (IVVD) Investor Alert: Robbins LLP Reminds Investors of Pending Lead Plaintiff Deadline in Invivyd, Inc. Class Action

March 24, 2023 | benzinga.com

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

March 22, 2023 | benzinga.com

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

March 17, 2023 | prnewswire.com

IVVD SHAREHOLDER ALERT: Jakubowitz Law Reminds Invivyd Shareholders of a Lead Plaintiff Deadline of April 3, 2023

See More Headlines

IVVD Price History

30 days | 90 days | 365 days | Advanced Chart

IVVD Company Calendar

Last Earnings: 3/23/2023
Today: 6/09/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IVVD
CUSIP: N/A
CIK: 1832038
Web: adagiotx.com
Phone: 781-819-0080
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +129.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-241,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.74%
Return on Assets: -42.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.62
Quick Ratio: 15.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.27 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 109,480,000
Free Float: 88,571,000
Market Cap: $143.42 million
Optionable: Optionable
Beta: 0.11

Key Executives

Mr. David Hering M.B.A. (Age 47)
CEO & Director
Comp: $453.76k

Ms. Jill Andersen J.D. (Age 49)
Chief Legal Officer & Corp. Sec.
Comp: $580.12k

Ms. Laura Walker Ph.D. (Age 37)
Co-Founder & Chief Scientific Officer

Mr. Frederick W. Driscoll (Age 71)
Interim CFO, Principal Financial Officer & Principal Accounting Officer

Mr. Jeremy Gowler
Chief Operating & Commercial Officer

Dr. Rebecca Dabora Ph.D. (Age 63)
Chief Technology & Manufacturing Officer

Kyra Rosow Faircloth
VP of Gov. Affairs, Advocacy & Corp. Communication

Dr. Peter C. Schmidt M.D.
M.Sc., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IVVD Stock - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares.
View IVVD analyst ratings or view top-rated stocks.
What is Invivyd's stock price forecast for 2023?: 2 analysts have issued 12-month target prices for Invivyd's shares. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 129.0% from the stock's current price.
View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts.
How have IVVD shares performed in 2023?: Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have decreased by 12.7% and is now trading at $1.31.
View the best growth stocks for 2023 here.
When is Invivyd's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our IVVD earnings forecast.
How were Invivyd's earnings last quarter?: Invivyd, Inc. (NASDAQ:IVVD) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.02.
What ETF holds Invivyd's stock ?: ETFMG Treatments Testing and Advancements ETF holds 35,155 shares of IVVD stock, representing 0.23% of its portfolio.

What is Invivyd's stock symbol?: Invivyd trades on the NASDAQ under the ticker symbol "IVVD."
Who are Invivyd's major shareholders?: Invivyd's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (12.76%), Alphabet Inc. (5.20%), BlackRock Inc. (3.45%), Slate Path Capital LP (3.42%), Bain Capital Life Sciences Investors LLC (1.77%) and Maverick Capital Ltd. (1.73%).
How do I buy shares of Invivyd?: Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Invivyd's stock price today?: One share of IVVD stock can currently be purchased for approximately $1.31.
How much money does Invivyd make?: Invivyd (NASDAQ:IVVD) has a market capitalization of $143.42 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.
How can I contact Invivyd?: Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com.

This page (NASDAQ:IVVD) was last updated on 6/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial